Semaglutide is a synthetic long-acting GLP-1 receptor agonist peptide widely used in metabolic research. It simulates the function of endogenous GLP?1 hormone in a glucose-dependent manner. When blood glucose rises, it promotes insulin secretion and suppresses glucagon secretion to lower blood glucose. It also delays gastric emptying, enhances satiety signals and reduces food intake. This molecule is commonly applied in laboratory studies focusing on type 2 diabetes, obesity, insulin resistance and related metabolic complications.

Manufactured using solid-phase peptide synthesis technology, the crude peptide is purified by multi-step reversed-phase HPLC to remove truncated peptide fragments, oxidative impurities and residual organic solvents. Each batch is supplied with complete COA documents, including HPLC purity test, MS molecular weight verification, moisture detection, residual solvent analysis, endotoxin and microbial limit testing to ensure stable batch consistency. The lyophilized powder form greatly reduces peptide hydrolysis and degradation, maintaining reliable quality during international transportation. Suitable research applications include in vitro cell receptor binding tests, intracellular signal pathway exploration, in vivo animal pharmacodynamic studies and peptide stability testing.